| Schedule of Share Capital Information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nature of the Transactions |
|
Share Capital |
|
|
Share premium |
|
|
Number of shares |
|
|
Nominal value |
|
|
$ in thousands (except number of shares) |
|
|
in € |
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2025 |
|
|
5,889 |
|
|
|
494,288 |
|
|
|
100,093,873 |
|
|
0.05 |
Allocation of prior period loss |
|
|
|
|
|
(62,999 |
) |
|
|
|
|
|
Exercise of share warrants, employee warrants, stock-options and free-shares vesting |
|
|
13 |
|
|
|
3 |
|
|
|
231,356 |
|
|
|
Non-cash stock-based compensation expense |
|
|
- |
|
|
|
2,258 |
|
|
|
- |
|
|
|
Balance as of June 30, 2025 |
|
|
5,902 |
|
|
|
433,549 |
|
|
|
100,325,229 |
|
|
0.05 |
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2026 |
|
|
5,903 |
|
|
|
437,445 |
|
|
|
100,339,441 |
|
|
0.05 |
Allocation of prior period loss |
|
|
- |
|
|
|
(69,847 |
) |
|
|
- |
|
|
|
Exercise of share warrants, employee warrants, stock-options and vesting of free-shares (1) |
|
|
21 |
|
|
|
198 |
|
|
|
358,717 |
|
|
|
Non-cash stock-based compensation expense |
|
|
- |
|
|
|
3,952 |
|
|
|
- |
|
|
|
Balance as of June 30, 2026 |
|
|
5,924 |
|
|
|
371,749 |
|
|
|
100,698,158 |
|
|
0.05 |
Capital evolution during the six-month period ended June 30, 2026 (1) During the six-month period ended June 30, 2026, 358,717 ordinary shares were issued to the benefit of Cellectis employees related to free share plans which met vesting conditions and exercises of stock-options.
|